Glenn J. Bubley

56.4k total citations · 5 hit papers
169 papers, 12.2k citations indexed

About

Glenn J. Bubley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Glenn J. Bubley has authored 169 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 35 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Glenn J. Bubley's work include Prostate Cancer Treatment and Research (119 papers), Prostate Cancer Diagnosis and Treatment (41 papers) and Hormonal and reproductive studies (30 papers). Glenn J. Bubley is often cited by papers focused on Prostate Cancer Treatment and Research (119 papers), Prostate Cancer Diagnosis and Treatment (41 papers) and Hormonal and reproductive studies (30 papers). Glenn J. Bubley collaborates with scholars based in United States, Canada and Israel. Glenn J. Bubley's co-authors include Steven P. Balk, PF Weller, Mary‐Ellen Taplin, Eric J. Small, Philip W. Kantoff, Yoo-Joung Ko, Todd D. Shuster, Phillip G. Febbo, Amy E. Spooner and Mark A. Rubin and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Glenn J. Bubley

167 papers receiving 12.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

2008 1.7k citations Howard I. Scher, Michael J. Morris et al. Journal of Clinical Oncology profile →
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer

1995 948 citations Mary‐Ellen Taplin, Glenn J. Bubley et al. profile →
Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer

2006 843 citations Glenn J. Bubley, Mark A. Rubin et al. Cancer Research profile →
The idiopathic hypereosinophilic syndrome

1994 657 citations Glenn J. Bubley et al. profile →
Biology of Prostate-Specific Antigen

2003 513 citations Steven P. Balk, Glenn J. Bubley et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Glenn J. Bubley

Since Specialization

Citations

This map shows the geographic impact of Glenn J. Bubley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn J. Bubley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn J. Bubley more than expected).

Fields of papers citing papers by Glenn J. Bubley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn J. Bubley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn J. Bubley. The network helps show where Glenn J. Bubley may publish in the future.

Co-authorship network of co-authors of Glenn J. Bubley

This figure shows the co-authorship network connecting the top 25 collaborators of Glenn J. Bubley. A scholar is included among the top collaborators of Glenn J. Bubley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glenn J. Bubley. Glenn J. Bubley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Richard M. Hoffman, Paul L. Nguyen, Dana E. Rathkopf, (unknown), Daniel E. Spratt, Robert T. Dess, (unknown), Russell Z. Szmulewitz, David J. Einstein, Glenn J. Bubley, James B. Yu, Yi An, Anthony Wong, (unknown), (unknown), Brent S. Rose, (unknown), Adam S. Kibel, Mary‐Ellen Taplin, Marisa Kollmeier	0
2	FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP) 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Paul L. Nguyen, Marisa Kollmeier, Dana E. Rathkopf, Richard M. Hoffman, (unknown), Daniel E. Spratt, Robert T. Dess, Stanley L. Liauw, Russell Z. Szmulewitz, David J. Einstein, Glenn J. Bubley, James B. Yu, Yi An, Anthony Wong, (unknown), (unknown), Brent S. Rose, (unknown), Adam S. Kibel, Mary‐Ellen Taplin	1
3	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance 2021 ·Clinical Cancer Research ·Rana R. McKay, Lucia Kwak, Jett Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, Bruce Montgomery, Mary‐Ellen Taplin	21
4	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone 2019 ·Journal of Clinical Oncology ·Rana R. McKay, Huihui Ye, Wanling Xie, Rosina T. Lis, Carla Calagua, Zhenwei Zhang, Quoc‐Dien Trinh, Steven L. Chang, Lauren C. Harshman, Ashley E. Ross, Kenneth J. Pienta, Daniel W. Lin, William J. Ellis, Bruce Montgomery, Peter Chang, Andrew A. Wagner, Glenn J. Bubley, Adam S. Kibel, Mary-Ellen Taplin	76
5	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer 2019 ·JCO Precision Oncology ·(unknown), Shana Y. Trostel, (unknown), Olga Voznesensky, Rachel Schaefer, Nichelle C. Whitlock, Scott Wilkinson, (unknown), (unknown), Steven Shema, Ross Lake, (unknown), David J. Einstein, Fatima Karzai, James L. Gulley, Peter Chang, Glenn J. Bubley, Steven P. Balk, Huihui Ye, Adam G. Sowalsky	49
6	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations 2018 ·Cancer Research ·Adam G. Sowalsky, Huihui Ye, Manoj Bhasin, Eliezer M. Van Allen, Massimo Loda, Rosina T. Lis, Laleh Montaser‐Kouhsari, Carla Calagua, Fen Ma, Joshua W. Russo, Rachel Schaefer, Olga Voznesensky, Zhenwei Zhang, Glenn J. Bubley, Bruce Montgomery, Elahe A. Mostaghel, Peter S. Nelson, Mary‐Ellen Taplin, Steven P. Balk	38
7	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide 2017 ·Clinical Cancer Research ·Carla Calagua, Joshua W. Russo, Yue Sun, Rachel Schaefer, Rosina T. Lis, Zhenwei Zhang, Kathleen M. Mahoney, Glenn J. Bubley, Massimo Loda, Mary‐Ellen Taplin, Steven P. Balk, Huihui Ye	63
8	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer 2016 ·Clinical Cancer Research ·Rana R. McKay, Lillian Werner, Elahe A. Mostaghel, Rosina T. Lis, Olga Voznesensky, Zhenwei Zhang, Brett T. Marck, Alvin M. Matsumoto, Liran Domachevsky, Katherine Zukotynski, Manoj Bhasin, Glenn J. Bubley, Bruce Montgomery, Philip W. Kantoff, Steven P. Balk, Mary‐Ellen Taplin	28
9	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors 2014 ·Clinical Cancer Research ·(unknown), Adam G. Sowalsky, Shuai Gao, Changmeng Cai, Olga Voznesensky, Rachel Schaefer, Massimo Loda, Lawrence D. True, Huihui Ye, Patricia Troncoso, (unknown), Philip W. Kantoff, Bruce Montgomery, Peter S. Nelson, Glenn J. Bubley, Steven P. Balk, Mary-Ellen Taplin	139
10	Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer 2014 ·Molecular Cancer Research ·Adam G. Sowalsky, Zheng Xia, Liguo Wang, Hao Zhao, Shaoyong Chen, Glenn J. Bubley, Steven P. Balk, Wěi Li	84
11	Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4 2012 ·Cancer Research ·Adam G. Sowalsky, Huihui Ye, Glenn J. Bubley, Steven P. Balk	65
12	Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors 2011 ·Cancer Research ·Changmeng Cai, Sen Chen, Patrick Kwok‐Shing Ng, Glenn J. Bubley, Peter S. Nelson, Elahe A. Mostaghel, Brett T. Marck, Alvin M. Matsumoto, Nicholas I. Simon, Hongyun Wang, Shaoyong Chen, Steven P. Balk	349
13	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer 2010 ·Journal of Clinical Oncology ·Daniel C. Danila, Michael J. Morris, Johann S. de Bono, Charles J. Ryan, Samuel R. Denmeade, Matthew R. Smith, Mary-Ellen Taplin, Glenn J. Bubley, Thian Kheoh, Christopher M. Haqq, Arturo Molina, Aseem Anand, (unknown), Steven M. Larson, Lawrence H. Schwartz, Martin Fleisher, Howard I. Scher	318
14	MUC1 oncoprotein is a druggable target in human prostate cancer cells 2009 ·Molecular Cancer Therapeutics ·Maya Datt Joshi, Rehan Ahmad, Yin Li, Deepak Raina, Hasan Rajabi, Glenn J. Bubley, Surender Kharbanda, Donald Küfe	63
15	Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer 2009 ·Clinical Cancer Research ·Mohamed S. Arredouani, Bin Lu, Manoj Bhasin, (unknown), Wen Yue, Juan‐Miguel Mosquera, Glenn J. Bubley, Vivian Li, Mark A. Rubin, Towia A. Libermann, Martin G. Sanda	142
16	The Challenge of Herbal Therapies for Prostate Cancer 2008 ·Clinical Cancer Research ·Rupal S. Bhatt, Glenn J. Bubley	3
17	Hypoxia‐inducible factor‐2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor 2008 ·British Journal of Urology ·Rupal S. Bhatt, Daniel M. Landis, Michael Zimmer, (unknown), Shaoyong Chen, Vikas P. Sukhatme, Othon Iliopoulos, (unknown), Glenn J. Bubley	24
18	Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. 2003 ·PubMed ·Sabrina Rossi, Edgard Graner, Phillip G. Febbo, Lisa J. Weinstein, Nandita Bhattacharya, (unknown), Glenn J. Bubley, Stephen Balk, Massimo Loda	231
19	Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer 2001 ·The Journal of Immunology ·Syed Muhammad Tahir, Olivia Cheng, Angela Shaulov, Yasuhiko Koezuka, Glenn J. Bubley, S. Brian Wilson, Steven P. Balk, Mark A. Exley	320
20	Antisense TRPM‐2 Oligodeoxynucleotides Chemosensitize Human Androgen Independent PC‐3 Prostate Cancer Cells both In Vitro and In Vivo. 2000 ·Glenn J. Bubley	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact